Diabetes

Top Story

Twice-daily aspirin may confer CV benefit in type 2 diabetes

Twice-daily aspirin may confer CV benefit in type 2 diabetes
September 18, 2017

Patients with type 2 diabetes but without existing cardiovascular disease experienced a time-dependent increase in platelet aggregation in the 24 hours after once-daily aspirin therapy, suggesting that a twice-daily aspirin regimen could provide CV benefit, study data show.

“The antiplatelet effects of aspirin do not last for the standard 24-hour dosing interval, and patients with type 2 diabetes have alterations in their platelet function,” Liv Vernstrøm, a master’s student in the department of endocrinology and internal medicine at Aarhus University in Denmark, told Endocrine Today. “Perhaps the alterations seen in platelet function in patients with type 2 diabetes could be related to their increased risk for CVD. Further, they might benefit from an alternative dosing regimen when it comes to treatment with aspirin. Our data indicate that a twice-daily dosing could add additional benefits, but this needs to be studied further.”

Meeting News

DEVOTE: Hypoglycemia, glycemic variability increase mortality risk in type 2 diabetes

September 15, 2017
In adults with type 2 diabetes, higher day-to-day fasting glycemic variability and severe hypoglycemia are independently associated with all-cause mortality, according…
Meeting News

CV death risk decreases with evolocumab in atherosclerotic disease

September 15, 2017
The risks for cardiovascular death, myocardial infarction and stroke are reduced in adults with atherosclerotic disease with or without diabetes treated with the PCSK9…
Meeting News

Acarbose fails to lower risk for major adverse CV events in CHD

September 13, 2017
The risk for major adverse cardiovascular events was not reduced in Chinese adults with coronary heart disease treated with acarbose, but the therapy was effective in…
More Headlines »
CME

Individualizing Antihypertensive Therapy to Meet Today’s Needs of Patients and Providers

This activity is supported by an educational grant from Allergan, Inc.

High blood pressure is a leading cause of cardiovascular disease and death in the United States and is often called…
More »
Video
Meeting News

VIDEO: Glycemic control key to avoid CV complications in diabetes

July 14, 2017
More »
Resource Centers
Cardiology Today Anniversary Resource Center

Cardiology Today Anniversary Resource Center

Video
Meeting News Coverage

VIDEO: PEGASUS-TIMI 54 analysis shows reduced risk for MACE in patients with diabetes

April 7, 2016
More »
Advertisement
Advertisement